pSivida Corp. Share Price Nasdaq

Stocks

09/16/09	PSivida : Primary Endpoint Met in pSivida's Utilization Study of New Medidur™ Inserter with Smaller Diameter Needle	PU
14/16/14	PSivida : Investigator-Sponsored Phase 2 Study Results Show pSivida's Medidur® Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve	PU
02/16/02	PSivida : Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe	PU
28/15/28	PSivida : Announces NDA for Medidur™ Now Planned Using Six-Month Efficacy Data from Both Phase III Trials; FDA Concurs	BU
14/15/14	PSivida : CEO to Present at Ladenburg Thalmann 2015 Healthcare Conference September 29, 2015	BU

1 day

-0.87%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PSIVIDA CORP.	-0.87%	-2.40%	-	-	0
WUXI APPTEC CO., LTD.	+4.16%	-0.30%	+58.96%	+94.17%	7.15TCr
ARGENX SE	-0.19%	+1.32%	+37.20%	+81.33%	6.01TCr
LONZA GROUP AG	-1.16%	+2.78%	+9.52%	+37.31%	4.89TCr
IQVIA HOLDINGS INC.	+0.67%	+1.24%	+42.77%	+39.87%	4.43TCr
REVOLUTION MEDICINES, INC.	+1.62%	+9.36%	+346.66%	+697.06%	4.38TCr
BEONE MEDICINES AG	+2.08%	+2.09%	+9.37%	+108.76%	4.15TCr
CELLTRION, INC.	-0.67%	-0.45%	+4.47%	+46.37%	3.01TCr
WUXI BIOLOGICS (CAYMAN) INC.	+4.77%	+6.46%	+41.54%	+22.78%	2.8TCr
INSMED INCORPORATED	+0.02%	-2.37%	-19.78%	+355.38%	2.53TCr
Average	+0.99%	+0.48%	+58.97%	+164.78%	4.37TCr
Weighted average by Cap.	+1.30%	+0.63%	+64.02%	+155.75%